AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10806604
Drug: Tenecteplase (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (30, 40, or 50 mg intravenous bolus)
Trial: 10806604
Drug: Alteplase (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (100 mg intravenous as accelerated 90-minute infusion)
Trial: 10806604
Drug: Tenecteplase (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (approximately 0.5 mg/kg)
Trial: 7639163
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg verapamil
Trial: 7639163
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg verapamil
Trial: 7639163
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg verapamil
Trial: 7639163
Drug: 540 mg
RxNorm normalized name: lecithin 540 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 540 mg verapamil
Trial: 6679514
Drug: Lisuride (0.0250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride (0.0250 mg single oral dose)
Trial: 30839426
Drug: Positive treatment-related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive treatment-related suggestions
Trial: 28552083
Drug: Maudsley Model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maudsley Model Anorexia Nervosa Treatment for Adults
Trial: 28552083
Drug: Enhanced Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Cognitive Behavioural Therapy
Trial: 26316741
Drug: Olodaterol 2
RxNorm normalized name: OLODATEROL 2.5MCG/ACTUAT 14D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olodaterol 2 µg
Trial: 26316741
Drug: Olodaterol 5
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 5 µg
Trial: 26316741
Drug: Olodaterol 10
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 10 µg
Trial: 23159168
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment in conjunction with orthognathic surgery
Trial: 22951790
Drug: 380 mg
RxNorm normalized name: aspirin 380 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 380 mg XR‐NTX
Trial: 19624833
Drug: Face-to-face group
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face group treatment programme
Trial: 16121931
Drug: Mitherapist (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitherapist (15 mg/dl Lentinan, particulate size of 0.2 microm)
Trial: 31953790
Drug: Diroximel fumarate
RxNorm normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Diroximel fumarate (DRF) 462 mg
Trial: 24888488
Drug: Siltuximab 15
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Siltuximab 15 mg/kg every 4 weeks + best supportive care (BSC)
Trial: 22356258
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg (partial responders adjusted to dosing every 8 weeks)
Trial: 22356258
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg (partial responders adjusted to dosing every 8 weeks)
Trial: 20530973
Drug: Epirubicin followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF: Epirubicin 100 mg/m² on day 1, CMF: 600 mg/m² cyclophosphamide, 40 mg/m² methotrexate, 600 mg/m² 5-fluorouracil on days 1 and 8)
Trial: 20530973
Drug: Paclitaxel followed
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel followed by epirubicin and vinorelbine (T-EV: Paclitaxel 175 mg/m² on day 1, Epirubicin 75 mg/m² on day 1, Vinorelbine 25 mg/m² on days 1 and 8)
Trial: 16485513
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg/day for the first month and 8 mg/day for the remaining 11 months)
Trial: 11920300
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B vaccine (recombinant Plasmodium falciparum ring‐infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) formulated in oil‐based adjuvant)
Trial: 10325814
Drug: Trophic feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trophic feeding (0.5 ml/h if birthweight < 1 kg, 1 ml/h if ≥ 1 kg) in addition to parenteral nutrition
Trial: 10421395
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition alone
Trial: 31572236
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride
Trial: 25710276
Drug: Topical BAK-preserved
RxNorm normalized name: benzalkonium Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical BAK-preserved tafluprost
Trial: 21570522
Drug: 1 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/d n3-PUFA
Trial: 21570522
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d n3-PUFA
Trial: 19770175
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy home program (OTHP) for 8 weeks
Trial: 19770175
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy home program (OTHP) for 4 weeks (continued for 8 weeks)
Trial: 19770175
Drug: No occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No occupational therapy home program (no OTHP)
Trial: 15580811
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C, 800 mg vitamin E, and 10 mg folate
Trial: 9740162
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) at 0.2 IU/kg/d subcutaneously for 4 weeks
Trial: 9740162
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dietary prescriptions only)
Trial: 7989939
Drug: Chemotherapy (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (adjuvant fluorouracil (5-FU)-based)
Trial: 25533572
Drug: Follow-up observation
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up observation (no treatment)
Trial: 22959395
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose multidetector computed tomography coronary angiography (MDCT)
Trial: 21982664
Drug: Anacetrapib (ANA)
RxNorm normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib (ANA) 150 mg
Trial: 21982664
Drug: Anacetrapib (ANA)
RxNorm normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib (ANA) 300 mg
Trial: 21982664
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (ATV) 20 mg with Anacetrapib
Trial: 18652550
Drug: Intradermal trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal trivalent inactivated influenza vaccine (15 or 21 microg of hemagglutinin per strain)
Trial: 20372053
Drug: Intramuscular control
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular control vaccine
Trial: 31925721
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg daily)
Trial: 12709465
Drug: COER verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COER verapamil (180 mg)
Trial: 12709465
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg) or Hydrochlorothiazide (12.5 mg)
Trial: 3003298
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) 25 mg orally
Trial: 3003298
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) + Naloxone (NAL) 0.4 mg bolus followed by 4.0 mg/h infusion
Trial: 29045820
Drug: 5-fluorouracil cream
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil cream
Trial: 29045820
Drug: methyl aminolevulinate
RxNorm normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methyl aminolevulinate photodynamic therapy (MAL-PDT)
Trial: 26718237
Drug: Physiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy plus medication
Trial: 24317794
Drug: Baseline subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline subcutaneous adiposity
Trial: 23090987
Drug: Dasatinib (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100-200 mg daily) + CCNU (90-110 mg/m2)
Trial: 20606413
Drug: Continuous erythropoietin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous erythropoietin receptor activator (CERA) once monthly
Trial: 20606413
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta therapy
Trial: 7644052
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 mg qid)
Trial: 2693431
Drug: Individualized pharmacokinetic
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized pharmacokinetic (PK) dosing of amikacin
Trial: 2693431
Drug: Standard (every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard (every 12 h) dosing of amikacin
Trial: 681132
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg thioridazine
Trial: 30785496
Drug: Oregano essential
RxNorm normalized name: Oregano
DrugBank: Oregano (DB10677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oregano essential oil (OEO) at 150 mg.kg‐1
Trial: 30785496
Drug: Oregano essential
RxNorm normalized name: Oregano
DrugBank: Oregano (DB10677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oregano essential oil (OEO) at 200 mg.kg‐1
Trial: 30785496
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (CT) with zinc bacitracin
Trial: 26605836
Drug: Ranibizumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.3 mg)
Trial: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg
Trial: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 400 mg
Trial: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg (2 doses)
Trial: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 400 mg (2 doses)
Trial: 22950861
Drug: Topiramate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (10 mg/kg once a day for the first 3 days of life) with moderate hypothermia
Trial: 22950861
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with moderate hypothermia alone
Trial: 21058473
Drug: G‐CSF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF plus acupuncture (A)
Trial: 16306522
Drug: Timolol (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (nonselective beta-blocker)
Trial: 10096387
Drug: Finasteride treatment
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride treatment for 24 to 30 months
Trial: 2291868
Drug: Captopril (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5, 25 and 50 mg)
Trial: 42628
Drug: Oxazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (15 mg)
Trial: 7316551
Drug: Topical exothermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical exothermic pads (hyperthermia)
Trial: 28875371
Drug: Heparin group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin group (heparin bolus 70 IU per kg body weight before PA catheter insertion)
Trial: 19909743
Drug: 5% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% mannitol meal (350 mL)
Trial: 19909743
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose meal (350 mL)
Trial: 17983937
Drug: Insulin sensitizers
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin sensitizers
Trial: 15636619
Drug: Preemptive standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive standard (IFN) or pegylated (peg-IFN) interferon alfa-2b (3 MU thrice weekly or 1.5 microg/kg weekly) plus ribavirin (600 mg increased to 1.0-1.2 g daily) initiated 2-6 weeks post-transplantation for 48 weeks
Trial: 15636619
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IFN/peg-IFN plus ribavirin)
Trial: 17889491
Drug: Oral gemifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gemifloxacin
Trial: 12132563
Drug: Oral clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clarithromycin
Trial: 10212514
Drug: Artesunate (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (700 mg oral for 5 days)
Trial: 7790130
Drug: Perceived peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived peer norms regarding drug-related risk reduction
Trial: 2127095
Drug: Cooperative Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooperative Care (CC) program
Trial: 7005645
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (cyclophosphamide 200 mg/m2 IV weekly x 4 and Adriamycin 40 mg/m2 IV weeks 1 and 3)
Trial: 7005645
Drug: No intensive
RxNorm normalized name: TITANIUM DIOXIDE 11.4072 g in 100 g TOPICAL POWDER [BUENO INTENSIVE FITTING CUSHION FOUNDATION SPF 50 PA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intensive treatment (control group)
Trial: 12107604
Drug: Leukotriene receptor
RxNorm normalized name: Leukotriene receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene receptor antagonists
Trial: 19132857
Drug: CSII with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII with RT-CGM as an adjunct to SMBG (n = 14)
Trial: 19132857
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDI) and self-monitoring of blood glucose (SMBG) (control arm)
Trial: 16508637
Drug: FOLFOXIRI (CPT‐11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI (CPT‐11 150 mg m(‐2) on d1, L‐OHP 65 mg m(‐2) on d2, LV 200 mg m(‐2) on days 2 and 3, 5‐FU 400 mg m(‐2) as i.v. bolus and 600 mg m(‐2) as 22 h i.v. continuous infusion on days 2 and 3, every 2 weeks)
Trial: 16508637
Drug: FOLFIRI (CPT‐11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (CPT‐11 180 mg m(‐2) on d1, LV and 5‐FU administered as in FOLFOXIRI, every 2 weeks)
Trial: 28439987
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg/day
Trial: 28634217
Drug: Participants taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Trial: 28634217
Drug: Participants not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants not taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Trial: 21350366
Drug: Engerix B,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix B, 20 μg HBsAg
Trial: 21350366
Drug: Engerix B,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix B, 40 μg
Trial: 21350366
Drug: Twinrix, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twinrix, 20 μg HBsAg combined with 720 ELU hepatitis A antigen
Trial: 9765723
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus supportive care
Trial: 9765723
Drug: Chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens containing cisplatin
Trial: 30542740
Drug: Chemotherapy (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (not specified)
Trial: 9765723
Drug: Chemotherapy using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy using long-term alkylating agents other than cisplatin
Trial: 3740675
Drug: Chemotherapy (general)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (general)
Trial: 3691624
Drug: Amodiaquine 200
RxNorm normalized name: amodiaquine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine 200 mg
Trial: 3691624
Drug: Amodiaquine 400
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine 400 mg
Trial: 3691624
Drug: Amodiaquine 600
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine 600 mg
Trial: 3691624
Drug: Amodiaquine 200
RxNorm normalized name: amodiaquine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine 200 mg, 400 mg, 600 mg
Trial: 23664208
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ranibizumab and PDT
Trial: 18158000
Drug: Training and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training and Support Program (TSP); 8 weekly sessions, 1 hour each, taught by qualified therapists.
Trial: 16259645
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d nemifitide
Trial: 16259645
Drug: 45 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/d nemifitide
Trial: 10674778
Drug: Respiratory syncytial
RxNorm normalized name: Respiratory syncytial virus Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory syncytial virus immune globulin intravenous (RSV‐IGIV)
Trial: 1280735
Drug: SCH 34826
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 34826 (400 mg every 6 hours for five doses)
Trial: 23259260
Drug: Conventional acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture therapy combined with conventional rehabilitation training
Trial: 21082868
Drug: Anacetrapib 100
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 100 mg daily for 18 months
Trial: 16190570
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with pegylated interferon
Trial: 16190570
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of consensus interferon and ribavirin
Trial: 11431944
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg tranexamic acid before skin incision and after the start of cardiopulmonary bypass
Trial: 11431944
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg tranexamic acid
Trial: 22840421
Drug: Lutein plus
RxNorm normalized name: Lutein Plus with Zeaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein plus zeaxanthin (L+Z) 10 mg/2 mg; n = 1044
Trial: 22840421
Drug: ω‐3 long‐chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 long‐chain polyunsaturated fatty acids (LCPUFA) (eicosapentaenoic acid + docosahexaenoic acid [650 mg/350 mg]; n = 1069)
Trial: 22840421
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L+Z and ω‐3 LCPUFAs; n = 1078
Trial: 22840421
Drug: Original AREDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original AREDS formulation with variations in zinc and β‐carotene
Trial: 20723301
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus dipyridamole (100 mg/day)
Trial: 29630101
Drug: Simple chemotherapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple chemotherapy
Trial: 15877873
Drug: Carbonated mineral
RxNorm normalized name: Mineral carbon
DrugBank: Graphite (DB18717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbonated mineral water (1 litre daily for 8 weeks)